PRCT:NSD-Procept Biorobotics Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 76.6

Change

0.00 (0.00)%

Market Cap

USD 4.10B

Volume

0.79M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-07 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 27.85B
PODD Insulet Corporation

N/A

USD 16.40B
BRKR Bruker Corporation

N/A

USD 9.94B
MASI Masimo Corporation

N/A

USD 6.03B
TMDX TransMedics Group Inc

N/A

USD 4.66B
AXNX Axonics Modulation Technologie..

N/A

USD 3.52B
QDEL Quidel Corporation

N/A

USD 3.06B
TNDM Tandem Diabetes Care Inc

N/A

USD 2.88B
LIVN LivaNova PLC

N/A

USD 2.64B
NARI Inari Medical Inc

N/A

USD 2.61B

ETFs Containing PRCT

W311:XETRA HAN-GINS Indxx Healthcare.. 1.22 % 0.00 %

N/A

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.22 % 0.00 %

N/A

USD 0.02B
FYC First Trust Small Cap Gro.. 0.78 % 0.70 %

N/A

USD 0.32B
FYX First Trust Small Cap Cor.. 0.40 % 0.63 %

N/A

USD 0.91B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

N/A

USD 0.22B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 82.77% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.77% 90% A- 95% A
Trailing 12 Months  
Capital Gain 130.45% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 130.45% 93% A 96% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 19.00% 69% C- 77% C+
Dividend Return 19.00% 69% C- 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.70% 71% C- 45% F
Risk Adjusted Return 46.68% 93% A 77% C+
Market Capitalization 4.10B 95% A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector